|
1
|
Lapierre A, Horn S, Créhange G, Enachescu C, Latorzeff I, Supiot S, Sargos P, Hennequin C, Chapet O. Radiothérapie stéréotaxique extracrânienne : quelle machine pour quelle indication ? Stéréotaxie prostatique. Cancer Radiother 2019; 23:651-657. [DOI: 10.1016/j.canrad.2019.06.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Accepted: 06/26/2019] [Indexed: 10/26/2022]
|
|
2
|
Kim SK, Wu CC, Horowitz DP. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. J Gastrointest Oncol 2016; 7:479-86. [PMID: 27284482 DOI: 10.21037/jgo.2015.10.01] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
With recent advances in imaging modalities and radiation therapy, stereotactic body radiotherapy (SBRT) has allowed for the delivery of high doses of radiation with accuracy and precision. As such, SBRT has generated favorable results in the treatment of several cancers. Although the role of radiation has been controversial for the treatment of pancreatic ductal adenocarcinoma (PDAC) due to rather lackluster results in clinical trials, SBRT may offer improved outcomes, enhance the quality of life, and aid in palliative care settings for PDAC patients. This review delineates the role of SBRT in the treatment of PDAC, presents the defining principles of radiation biology and the radiation oncology work flow, and discusses the prospects of new treatment regimens involving tumor immunology and radiation therapy.
Collapse
Affiliation(s)
- Samuel K Kim
- Department of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA
| | - Cheng-Chia Wu
- Department of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA
| | - David P Horowitz
- Department of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA
| |
Collapse
|
|
3
|
Supiot S, Clément-Colmou K, Paris F, Corre I, Chiavassa S, Delpon G. [Which rules apply to hypofractionated radiotherapy?]. Cancer Radiother 2015; 19:421-5. [PMID: 26321647 DOI: 10.1016/j.canrad.2015.05.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 05/18/2015] [Accepted: 05/19/2015] [Indexed: 12/22/2022]
Abstract
Hypofractionated radiotherapy is now more widely prescribed due to improved targeting techniques (intensity modulated radiotherapy, image-guided radiotherapy and stereotactic radiotherapy). Low dose hypofractionated radiotherapy is routinely administered mostly for palliative purposes. High or very high dose hypofractionated irradiation must be delivered according to very strict procedures since every minor deviation can lead to major changes in dose delivery to the tumor volume and organs at risk. Thus, each stage of the processing must be carefully monitored starting from the limitations and the choice of the hypofractionation technique, tumour contouring and dose constraints prescription, planning and finally dose calculation and patient positioning verification.
Collapse
Affiliation(s)
- S Supiot
- Département de radiothérapie, institut de cancérologie de l'Ouest Nantes-Angers, boulevard Jacques-Monod, 44805 Saint-Herblain, France; Centre de recherche en cancérologie Nantes-Angers, UMR Inserm 892, quai Moncousu, 44007 Nantes cedex 1, France; CNRS 6299, quai Moncousu, 44007 Nantes cedex 1, France.
| | - K Clément-Colmou
- Département de radiothérapie, institut de cancérologie de l'Ouest Nantes-Angers, boulevard Jacques-Monod, 44805 Saint-Herblain, France; Centre de recherche en cancérologie Nantes-Angers, UMR Inserm 892, quai Moncousu, 44007 Nantes cedex 1, France; CNRS 6299, quai Moncousu, 44007 Nantes cedex 1, France
| | - F Paris
- Centre de recherche en cancérologie Nantes-Angers, UMR Inserm 892, quai Moncousu, 44007 Nantes cedex 1, France; CNRS 6299, quai Moncousu, 44007 Nantes cedex 1, France
| | - I Corre
- Centre de recherche en cancérologie Nantes-Angers, UMR Inserm 892, quai Moncousu, 44007 Nantes cedex 1, France; CNRS 6299, quai Moncousu, 44007 Nantes cedex 1, France
| | - S Chiavassa
- Centre de recherche en cancérologie Nantes-Angers, UMR Inserm 892, quai Moncousu, 44007 Nantes cedex 1, France; CNRS 6299, quai Moncousu, 44007 Nantes cedex 1, France; Département de radiophysique, institut de cancérologie de l'Ouest Nantes-Angers, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| | - G Delpon
- Centre de recherche en cancérologie Nantes-Angers, UMR Inserm 892, quai Moncousu, 44007 Nantes cedex 1, France; CNRS 6299, quai Moncousu, 44007 Nantes cedex 1, France; Département de radiophysique, institut de cancérologie de l'Ouest Nantes-Angers, boulevard Jacques-Monod, 44805 Saint-Herblain, France
| |
Collapse
|
|
4
|
[What is the level of evidence of new techniques in prostate cancer radiotherapy?]. Cancer Radiother 2014; 18:501-8. [PMID: 25192625 DOI: 10.1016/j.canrad.2014.06.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 06/23/2014] [Accepted: 06/29/2014] [Indexed: 12/30/2022]
Abstract
Prostate cancer radiotherapy has evolved from the old 2D technique to conformal, and then to intensity-modulated radiation therapy (IMRT) and stereotactic radiotherapy. At the same time, image-guidance (IGRT) is routinely used. New techniques such as protontherapy or carbontherapy are being developed with the objective of increased efficacy, decreased treatment duration, toxicity or cost. This review summarizes the evidence-based medicine of new technologies in the treatment of prostate cancer.
Collapse
|